Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) shot 31.8 percent in price Thursday to $1.99. Volume was an astonishing 15,051,137 shares, whereas normal volume is below one million. The Texas-based biopharmaceutical concern announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

Intel Inc. (Nasdaq: INTC) traded in 69,323,510 shares, surpassing a full-day average of 54,361,400. Prices for the stock lost 1.2 percent to $20.69, as the fallout from the impending purchase of McAfee by Intel.

Thermogenesis Corp. (Nasdaq: KOOL) fell 11.6% to $3.28 Thursday, on volume of 358,525 shares, better than 3 ½ times its daily average. KOOL, a leading supplier of innovative products and services that process and store adult stem cells, said today it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC).